

Press release

Date: June 16, 2022

ImaginAb and DuChemBio Announce Manufacturing and Distribution Partnership

Inglewood, California and, South Korea – June 16th, 2022 - ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and radiopharmaceutical therapies (RPT), is delighted to announce that it has reached an agreement with radiopharmaceutical company, DuChemBio Co, Ltd., for them to manufacture and supply ImaginAb's proprietary investigational CD8 ImmunoPET agent, Zirconium ⁸⁹Zr-crefmirlimab berdoxam, to pharmaceutical sponsored clinical trials as well as Investigator Initiated Trials in South Korea.

In addition, the agreement with DuChemBio, which is South Korea's leading radiopharmaceutical company with the largest manufacturing capability, also opens distribution capacity to other Asian countries within which ImaginAb does not currently have established manufacturing and distribution partnerships.

The agreement allows for the manufacture and distribution of the agent to continue post regulatory approval of ImaginAb's CD8 technology.

William Le, Operations Vice President at ImaginAb, said: "ImaginAb is excited to be partnering with DuChemBio. The agreement is an important milestone as we expand our presence in Asia and provide Zirconium ⁸⁹Zr-crefmirlimab berdoxam in this new market and is part of our continued push to establish a leading global manufacturing and distribution network for our agent."

JongWoo Kim, President and CEO of DuChemBio: "We are delighted to be working with ImaginAb to supply, manufacture and distribute ImaginAb's proprietary CD8 ImmunoPET imaging technology to support international Pharma trials involving innovative immuno-oncology therapeutic development programs as well as local investigator initiated studies involving Zirconium ⁸⁹Zr-crefmirlimab berdoxam."

ENDS

About ImaginAb

ImaginAb Inc. is a biotechnology company focused on developing radiopharmaceutical imaging and therapy agents. ImaginAb engineers antibody fragments called Minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available PET Imaging technology and therapeutic isotopes, these novel Minibodies bind specifically to cell surface targets, providing physicians with a whole-body picture of immune activity and the potential to treat cancer. ImaginAb is advancing a diagnostic and therapeutic pipeline of Minibodies against both oncology and immunology targets.

The Company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine Ventures, TRC, Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. For more information, please visit www.imaginab.com

About CD8 ImmunoPET

The Zr 89 CD8 ImmunoPET agent (zirconium ⁸⁹Zr-crefmirlimab berdoxam) is a zirconium -labelled minibody that binds the CD8 receptor on human T cells and is used for quantitative, non-invasive PET imaging of CD8 T cells in patients. CD8 T cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases. As such, quantitative imaging of CD8 T cells can be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes.

About DuChemBio

Established in 2002, DuChemBio is the largest radiopharmaceutical firm and the undisputed leader in the field of oncology and neurology PET imaging tracers in South Korea. As a pioneer of a fully integrated nuclear diagnostics business model, DCB develops, manufactures, and commercializes radiopharmaceutical tracers for PET/CT and PET/MRI hybrid imaging. After the merger with Carecamp Inc in 2021, the company now operates 12 radio-pharmacy facilities across the country. DCB is closely collaborating with leading hospitals and research centers to develop and advance the field of nuclear medicine in South Korea. DCB has successfully launched novel proprietary radiopharmaceutical products both developed locally and licensed from international partners.

DuChemBio has been advised by BGM Associates GmbH, a Berlin-based strategy and transactions advisory firm focused on healthcare and life science industries.

For further information please contact:

ImaginAb

Ian Wilson

CEO

Email: info@imaginab.com

Phone: +1 310 645 1211

DuChemBio

Kini Kim

Managing Director

Email: kini.kim@duchembio.com

Phone: +82-2-332-4868